Citadel Advisors’s Annovis Bio ANVS Stock Holding History

Citadel Advisors’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$130K	Buy	58,300 +14,900	+34%	+$40.9K	﹤0.01%	11806
2025 Q4	$150K	Buy	43,400 +4,800	+12%	+$14.4K	﹤0.01%	11321
2025 Q3	$79.9K	Buy	38,600 +4,700	+14%	+$11.7K	﹤0.01%	11975
2025 Q2	$73.6K	Sell	33,900 -42,800	-56%	-$84.5K	﹤0.01%	11553
2025 Q1	$115K	Sell	76,700 -228,800	-75%	-$700K	﹤0.01%	11260
2024 Q4	$1.54M	Buy	305,500 +40,900	+15%	+$296K	﹤0.01%	6175
2024 Q3	$2.13M	Buy	264,600 +126,700	+92%	+$1.19M	﹤0.01%	5416
2024 Q2	$794K	Buy	137,900 +20,800	+18%	+$169K	﹤0.01%	7055
2024 Q1	$1.39M	Buy	117,100 +114,800	+4,991%	+$1.25M	﹤0.01%	6239
2023 Q4	$43K	Buy	+2,300	New	+$20.4K	﹤0.01%	11941

Other funds holding ANVS

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Citadel Advisors's ANVS Position: Q4 2025 in Review

Citadel Advisors sold out of Annovis Bio (ANVS) in Q4 2025, closing a stake of 174,345 shares — an estimated $524K sold.

Citadel Advisors first reported a position in ANVS in Q1 2021 and held it in 8 quarters. The position peaked at $1.18M in Q3 2021. 53 funds tracked by Wall St. Rank hold ANVS as of Q4 2025.

Citadel Advisors reported no remaining Annovis Bio position as of Q4 2025 after selling out during the quarter.
Citadel Advisors sold 174,345 Annovis Bio shares in Q4 2025, an estimated $524K.
Citadel Advisors first reported a position in Annovis Bio in Q1 2021 and held it in 8 quarters.
Citadel Advisors's Annovis Bio position peaked at $1.18M in Q3 2021.
53 funds tracked by Wall St. Rank held Annovis Bio as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.